DE602004032457D1 - Nten - Google Patents

Nten

Info

Publication number
DE602004032457D1
DE602004032457D1 DE602004032457T DE602004032457T DE602004032457D1 DE 602004032457 D1 DE602004032457 D1 DE 602004032457D1 DE 602004032457 T DE602004032457 T DE 602004032457T DE 602004032457 T DE602004032457 T DE 602004032457T DE 602004032457 D1 DE602004032457 D1 DE 602004032457D1
Authority
DE
Germany
Prior art keywords
fgf
discovery process
organism
administration
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004032457T
Other languages
German (de)
English (en)
Inventor
Jacques Bollekens
Salah-Dine Chibout
Jacky Vonderscher
Francois Legay
Andre Cordier
Ruben Papoian
Andreas Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602004032457D1 publication Critical patent/DE602004032457D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
DE602004032457T 2003-11-07 2004-11-05 Nten Expired - Lifetime DE602004032457D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51807303P 2003-11-07 2003-11-07
US57224704P 2004-05-18 2004-05-18
PCT/EP2004/012572 WO2005045044A2 (en) 2003-11-07 2004-11-05 Use of fibroblast growth factor fragments

Publications (1)

Publication Number Publication Date
DE602004032457D1 true DE602004032457D1 (de) 2011-06-09

Family

ID=34576820

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004032457T Expired - Lifetime DE602004032457D1 (de) 2003-11-07 2004-11-05 Nten

Country Status (7)

Country Link
US (3) US20090093398A1 (https=)
EP (1) EP1682665B1 (https=)
JP (1) JP5118851B2 (https=)
AT (1) ATE507296T1 (https=)
DE (1) DE602004032457D1 (https=)
ES (1) ES2365852T3 (https=)
WO (1) WO2005045044A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
JP2006347979A (ja) * 2005-06-17 2006-12-28 National Institute Of Advanced Industrial & Technology 創傷治療及び／又は創傷治癒促進のための薬剤
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US11308462B2 (en) 2014-05-13 2022-04-19 Clear Token Inc Secure electronic payment
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
US20230382966A1 (en) * 2020-10-27 2023-11-30 Indiana University Research And Technology Corporation Novel klotho interaction site in the c-terminus of fgf23
CN114940990B (zh) * 2022-06-20 2023-03-14 北京市神经外科研究所 与颅内动脉瘤相关的基因突变位点及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249125A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
ES2340662T3 (es) * 2000-07-19 2010-06-08 Advanced Research And Technology Institute Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
AU2002214286A1 (en) * 2000-11-15 2002-05-27 Akiko Itai Method of profiling protein
JP2002223753A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
CA2443719A1 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
EP1491628A4 (en) * 2002-03-29 2006-10-18 Nat Inst Of Advanced Ind Scien NEW GALACTOSTRANSFERASES, PEPTIDES AND THESE CODING NUCLEIC ACID
JPWO2003091427A1 (ja) * 2002-04-24 2005-09-02 関西ティー・エル・オー株式会社 近位尿細管に発現する腎疾患関連遺伝子群

Also Published As

Publication number Publication date
ES2365852T3 (es) 2011-10-11
JP5118851B2 (ja) 2013-01-16
US20090093398A1 (en) 2009-04-09
JP2007521799A (ja) 2007-08-09
EP1682665B1 (en) 2011-04-27
ATE507296T1 (de) 2011-05-15
WO2005045044A3 (en) 2005-11-10
US20130040882A1 (en) 2013-02-14
EP1682665A2 (en) 2006-07-26
HK1095160A1 (en) 2007-04-27
WO2005045044A2 (en) 2005-05-19
US20120028896A1 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
Jin et al. Conotoxins: chemistry and biology
DE602004032457D1 (de) Nten
Smart et al. The emerging role of TYRO3 as a therapeutic target in cancer
Lucas et al. Mapping the lectin-like activity of tumor necrosis factor
Lavergne et al. Optimized deep-targeted proteotranscriptomic profiling reveals unexplored Conus toxin diversity and novel cysteine frameworks
Guddat et al. Three-dimensional structure of the α-conotoxin GI at 1.2 Å resolution
DE3785615T2 (de) Hemmungsstoffe der serin-protease.
Ivanov et al. Peptidomics: a logical sequel to proteomics
Holford et al. Pruning nature: Biodiversity-derived discovery of novel sodium channel blocking conotoxins from Conus bullatus
Robinson et al. Discovery by proteogenomics and characterization of an RF-amide neuropeptide from cone snail venom
ATE209684T1 (de) Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung
Tettamanti et al. Phylogenesis of brain-derived neurotrophic factor (BDNF)‏ in vertebrates
Pan et al. Isolation and characterization of myrmexins, six isoforms of venom proteins with anti-inflammatory activity from the tropical ant, Pseudomyrmex triplarinus
Suire et al. Peptidic inhibitors of insulin-degrading enzyme with potential for dermatological applications discovered via phage display
Kingan et al. Characterization of two myotropic neuropeptides in the FMRFamide family from segmental ganglia of the moth Manduca sexta: candidate neurohormones and neuromodulators
JPH07504685A (ja) アゲレノプシス・アペルタ由来のカルシウムチャンネル阻害ポリペプチド
Gondokesumo et al. A Computational Study to Predict Wound Healing Agents from the Peel of the Mangosteen Garcinia mangostana L.) Extract
BRPI0414793A (pt) uso do fator anti-secretor
BRPI0406680A (pt) Métodos para selecionar um animal para ter propriedades desejadas genotìpicas ou fenotìpicas em potencial, para modular a trascrição de mrna de um gene igf2 em uma célula ou organismo provido com referido gene e para identificar um composto, composto, composição farmacêutica, e, uso de um composto
de Araujo et al. Do vicinal disulfide bridges mediate functionally important redox transformations in proteins?
Pandya et al. Integrative temporo-spatial, mineralogic, spectroscopic, and proteomic analysis of postnatal enamel development in teeth with limited growth
Luo et al. Neural detection of gases—carbon dioxide, oxygen—in vertebrates and invertebrates
Humpel et al. Monitoring release of neurotrophic activity in the brains of awake rats
Chua et al. Purification and characterization of the pink-Floyd Drillipeptide, a bioactive venom peptide from Clavus davidgilmouri (Gastropoda: Conoidea: Drilliidae)
DE69728654D1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus